Abstract: Some embodiments of the present invention provide pharmaceutical formulations, for treating atherosclerosis in a mammal, including a bile acid and/or a terpene atherosclerotic plaque emulsifier. Some embodiments provide methods for administering such pharmaceutical formulations. In some embodiments, pharmaceutical formulations include a combination of a bile acid and a terpene in amounts effective to result in plaque regression, and the amount of each individual emulsifier in the combination can be lower than an amount that is effective to result in plaque regression when the emulsifier is administered alone. In some embodiments, a statin can be administered simultaneously or sequentially with the pharmaceutical formulation.

Abstract: Embodiments of methods of treating atherosclerosis are described. In some embodiments an emulsifier is provided to achieve levels in the systemic circulation that are effective to solubilize atherosclerotic plaque, resulting in plaque regression. In some embodiments, levels of greater than 50 ?M are achieved; in some embodiments levels ranging from about 100 ?M to about 600 ?M are achieved; in some embodiments, levels ranging from about 100 ?M to about 300 ?M are achieved. Emulsifiers can include bile salts, saponins, and ionic, nonionic, and zwitterionic detergents, or salts, conjugates, hydrates, solvates, or polymorphs thereof. In some embodiments, a statin can be administered simultaneously or sequentially with an emulsifier.

Abstract: Topical dermatological preparations including one or more lipodissolving, lipolytic, or adipocyte-disrupting substances for treatment of localized adiposity can include carbamide peroxide and a terpene such as d-limonene. In some embodiments, the preparations can include carbamide peroxide as a first component and, as a second component, at least one peppermint oil terpene, peppermint oil, or a compound isolated or derived from peppermint oil.

Abstract: Embodiments of methods of treating atherosclerosis are described. In some embodiments an emulsifier is provided to achieve levels in the systemic circulation that are effective to solubilize atherosclerotic plaque, resulting in plaque regression. In some embodiments, levels of greater than 50 ?M are achieved; in some embodiments levels ranging from about 100 ?M to about 600 ?M are achieved; in some embodiments, levels ranging from about 100 ?M to about 300 ?M are achieved. Emulsifiers can include bile salts, saponins, and ionic, nonionic, and zwitterionic detergents, or salts, conjugates, hydrates, solvates, or polymorphs thereof. In some embodiments, a statin can be administered simultaneously or sequentially with an emulsifier.

Abstract: A topical pharmacological preparation in the form of cream, suppositories or drops delivered topically to the vagina in order to contract the smooth muscle of the vaginal wall. The preparation contains a smooth muscle contracting agent such as oxytocin capable of constrict the vaginal tube reducing its overall diameter for a more pleasurable sexual experience for the female subject and his partner alike. The smooth muscle contracting agent can be associated with a systemic absorption retardant such as a mixture of Benzyl Alcohol, Acetone and Isopropanol. Such a formulation achieves high local tissue concentration of the smooth muscle contraction substance such as oxytocin in vicinity to the site of application, via minimization of systemic absorption of the smooth muscle contraction inducing substance and at the same time via promotion of its submucosal absorption across the mucosal barrier.

Abstract: A novel urinary catheter having an helicoidally threaded , screw shaped tip to facilitate insertion of the catheter tip by rotation into the bladder, especially useful in situation of difficult passage and entry into the bladder through a stenotic prostatic urethra. The operator instead of advancing the catheter by axial loading as it is presently done with ordinary catheters will rotate the urinary catheter along its longitudinal axis . Rotation of the catheter is transmitted to its specially designed screw shaped tip facilitating its engagement, advancement and insertion into the bladder through a stenotic segment of the urethral canal.

Abstract: Some embodiments of the present invention provide pharmaceutical formulations, for treating atherosclerosis in a mammal, including a bile acid and/or a terpene atherosclerotic plaque emulsifier. Some embodiments provide methods for administering such pharmaceutical formulations. In some embodiments, pharmaceutical formulations include a combination of a bile acid and a terpene in amounts effective to result in plaque regression, and the amount of each individual emulsifier in the combination can be lower than an amount that is effective to result in plaque regression when the emulsifier is administered alone. In some embodiments, a statin can be administered simultaneously or sequentially with the pharmaceutical formulation.

Abstract: Embodiments of methods of treating atherosclerosis are described. In some embodiments an emulsifier is provided to achieve levels in the systemic circulation that are effective to solubilize atherosclerotic plaque, resulting in plaque regression. In some embodiments, levels of greater than 50 ?M are achieved; in some embodiments levels ranging from about 100 ?M to about 600 ?M are achieved; in some embodiments, levels ranging from about 100 ?M to about 300 ?M are achieved. Emulsifiers can include bile salts, saponins, and ionic, nonionic, and zwitterionic detergents, or salts, conjugates, hydrates, solvates, or polymorphs thereof. In some embodiments, a statin can be administered simultaneously or sequentially with an emulsifier.

Abstract: A phyto-pharmacological substance, namely a saponin, precursor or derivative, with emulsifying/detergent/surfactant/fat dissolving properties administered into the systemic circulation of a subject via a variety of routes of administration including the topical-dermatological such as a skin patch, the oral-digestive in association with solubility or permeability or stability enhancers, alone or in synergitic combination, the topical-mucous membrane administration such as the sublingual route, the intravenous, subcutaneous, rectal, intramuscular, intradermal, inhalatory in form of inhaled microcrystals, the intrarterial, the saponin substance reaching and dissolving with its emulsifying properties the cholesterol aggregates and in general the lipidic core within the atherosclerotic plaque.

Abstract: A biocompatible lipid solubilzer, preferably a biliary acid or salt or a biliary precursor or derivative being made bioavailable in the systemic circulation of a patient via a variety of routes of administration including topical-mucous membrane, topical-dermatological such as via a skin patch, intravenous, subcutaneous, rectal, intramuscular, intradermal, inhalatory, intrarterial, or via specialized catheter for in loco delivery of the substance, or via a subcutaneous or intravenous infusion pump, the lipid solubilizer being capable of crossing the fibrous cap of the atherosclerotic plaque to reach and dissolve the cholesterol aggregates and in general the lipidic core within the plaque. As a result of such solubilization of the lipidic core of the plaque, the solubilized cholesterol exits the plaque and enters finely dissolved into the systemic circulation leaving behind a delipidized plaque.

Abstract: A pharmacological substance namely a biliary salt or acid or precursor or derivative with emulsifying properties administered into the systemic circulation of a patient via a variety of routes of administration including topical-mucous membrane such as sublingual, topical-dermatological such as via a skin patch, intravenous, subcutaneous, rectal, intramuscular, intradermal, inhalatory in form of inhaled microcrystals, intrarterial, systemic, or via specialized catheter for in loco delivery of the substance, or via a subcutaneous infusion pump, bedside type or compact/portable, said substance being capable of crossing the fibrous cap of the atherosclerotic plaque to reach and dissolving with its emulsifying properties the cholesterol aggregates and in general the lipidic core within the plaque.

Abstract: A pharmacological substance namely a biliary salt or acid or precursor or derivative with emulsifying properties administered into the systemic circulation of a patient via a variety of routes of administration including topical-mucous membrane such as sublingual, topical-dermatological such as via a skin patch, intravenous, subcutaneous, rectal, intramuscular, intradermal, inhalatory in form of inhaled microcrystals, intrarterial, systemic, or via specialized catheter for in loco delivery of the substance, said substance being capable of crossing the fibrous cap of the atherosclerotic plaque to reach and dissolving with its emulsifying properties the cholesterol aggregates and in general the lipidic core within the plaque. The solubilized cholesterol exits the plaque and enters finely dissolved into the systemic circulation leaving behind a plaque emptied of its lipid content: the plague appears as a virtual cavity roofed by the fibrous cap.

Abstract: A dermatological topical preparation such as a cream, a lotion, an emulsion, a paste, an ointment and the likes where a lipo-dissolving emulsifier such as a biliary compound is transdermally delivered through the superficial layers of the skin into the subcutaneous adipose tissue with the use of skin permeability enhancers. Some of these skin permeability enhancers are cyclodextrins, while others are substances which have the peculiar property of enhancing delivery of the lipo-dissolving substance locally into the adipose subcutaneous tissue maximizing subcutaneous uptake while minimizing systemic absorption in order to achieve maximization of local effect.

Abstract: A dermatological device for subcision of sub-epidermic tissues. The device is provided with a blunt dermis contacting surface enabling the operator to lift or cause traction to the skin from underneath the skin, after placement of the dermal contacting surface of the device under the skin. By mere skin lifting from underneath, fibrous bands present within the dermis are detached/disrupted/dissected from their attachments to the skin or from their attachments to deeper layers. Detachment/disruption/dissection of the fibrous bands can be aided by the adjunct of a dissecting arm which by rotation can enhance detachment/disruption/dissection of the fibrous bands. Pathological skin conditions such as edematous-fibrosclerotic panniculopathy known also as cellulite or any depressed scar or deep wrinkle can benefit from the device as dissection of the fibrous bands. which cause depression of skin areas. restitutes a nearly anatomical evened up skin surface.

Abstract: A dermatological device for subcision of sub-epidermic tissues. The device is provided with a blunt dermis contacting surface enabling the operator to lift or cause traction to the skin from underneath the skin, after placement of the dermal contacting surface of the device under the skin. Placement of the dermal contacting surface of the device under the skin is achieved by penetration of the skin of a patient via a sharp tip of a stylet housed within the device. By mere skin lifting from underneath, fibrous bands present within the dermis are detached/disrupted/dissected from their attachments to the skin or from their attachments to deeper layers. Detachment/disruption/dissection of the fibrous bands can be aided by the adjunct of a dissecting arm which by rotation can enhance the detachment/disruption/dissection of the fibrous bands.

Abstract: A dermatological device for infra-epidermic subcision via blunt dissection of fibrous bands of the edematous-fibrosclerotic panniculopathy, including a needle and a subepidermic skin layer anchoring member such as a balloon in flow communication with the needle. The fibrous bands are dissected bluntly by the balloon via dissection parallel to the surface of the skin as result of radial balloon expansion and via dissection perpendicular to the surface of the skin caused by traction on the skin induced by traction exerted by the operator upon the device.

Abstract: A dermatological topical preparation such a cream, a lotion, an emulsion, a paste, an ointment and the likes including liposomes carrying lipo-dissolving substances encapsulated by the liposomes wall or incorporated with the liposomes wall components. The lipo-dissolving substance is released by the liposomes into the target adipose tissue or its proximity after penetration of the superficial skin layers by the liposomes carrying the lipo-dissolving substance.

Abstract: A catamenial device for blood leakage prevention composed of an inflatable-expandable member and an absorbent intravaginal member such as a tampon. The inflatable-expandable member houses a resiliently expandable inflation member generally made of open cell foam. Prior insertion into a vaginal canal, the inflation member is in a contracted state. Upon placement to proper vaginal location, the inflation member expands by resiliency drawing air from a space inside the balloon or a reservoir of the balloon where the air has been displaced and housed when the air has been squeezed out from the open cell foam when the inflation member has been compressed prior to insertion. Inflation-expansion of the inflatable member can be activated manually by the user or via an intravaginal applicator which has the dual function of inserting and delivering the device into the vagina and that of actuating the inflation-expansion of the inflatable member.

Abstract: A catamenial device for blood leakage prevention composed of an inflatable-expandable member and an absorbent intravaginal member such as a tampon. The inflatable-expandable member houses a resiliently expandable inflation member generally made of open cell foam.[, and has an opening for airflow communication between the interior of the inflatable member and the outside environment. During]. Prior insertion into a vaginal canal, the inflation member is [inserted] in a contracted state. Upon placement to proper vaginal location, the inflation member expands by resiliency drawing air from a space inside the balloon or a reservoir of the balloon where the air has been displaced and housed when the air has been squeezed out from the open cell foam when the inflation member has been compressed prior to insertion. [outside environment into the inflatable member via the opening in the inflatable member within the balloon].

Abstract: An intravaginal inflatable member impermeable to fluids capable when inflated of providing sealable closure of the vaginal canal for the prevention of exit of menstrual blood from the vaginal orifice. The inflatable member can be connected to an absorbent member or can be a stand alone device. Inflation of the inflatable member can be activated manually by the user or via an intravaginal applicator which has the dual function of inserting and delivering the device into the vagina and that of actuating the source of inflation to inflate the inflatable member.